Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5793-5801

  Tokizane, Takashi ^a   Shiina, Hiroaki ^b   Igawa, Mikio ^b   Enokida, Hideki ^a   Urakami, Shinji ^a   Kawakami, Toshifumi ^a   Ogishima, Tatsuya ^a   Okino, Steven T ^a   Li, Long Cheng ^a   Tanaka, Yuichiro ^a   Nonomura, Norio ^c   Okuyama, Akihiko ^c   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHIMANE UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 5 AZA 2' DEOXYCYTIDINE; AROMATIC HYDROCARBON RECEPTOR; CARRIER PROTEIN; CYTOCHROME P450 1B1; HYPOXIA INDUCIBLE FACTOR 1BETA; MESSENGER RNA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYP1B1 GENE; DIOXIN RESPONSIVE ELEMENT; DNA HYPOMETHYLATION; DNA METHYLATION; DNA RESPONSIVE ELEMENT; DNA SEQUENCE; ENHANCER REGION; GENE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; MULTIGENE FAMILY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DNA BINDING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ARYL HYDROCARBON HYDROXYLASES; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 23844451055     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2545     Document Type: Article

References (38)

1. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I. International comparisons. BJU Int 2002;90:162-73.
2. Krstev S, Baris D, Stewart P, et al. Occupational risk factors and prostate cancer in U.S. blacks and whites. Am J Ind Med 1998;34:421-30.
3. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001;62:207-12.
4. Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 2001;41:297-316.
5. Cavalieri EL, Devanesan P, Bosland MC, Badawi AF, Rogan EG. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 2002;23:329-33.
6. Williams JA, Martin FL, Muir GH, Hewer A, Grover PL, Phillips DH. Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis 2000;21:1683-9.
7. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-31.
8. McFadyen MC, Breeman S, Payne S, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 1999;47:1457-64.
9. McFadyen MC, Cruickshank ME, Miller ID, et al. Cytochrome P450 CYP1B1 overexpression in primary and metastatic ovarian cancer. Br J Cancer 2001;85:242-6.
10. Carnell DM, Smith RE, Daley FM, et al. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys 2004;58:500-9.
11. Tang YM, Wo YY, Stewart J, et al. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 1996;271:28324-30.
12. Wo YY, Stewart J, Greenlee WF. Functional analysis of the promoter for the human CYP1B1 gene. J Biol Chem 1997;272:26702-7.
13. Shehin SE, Stephenson RO, Greenlee WF. Transcriptional regulation of the human CYP1B1 gene. Evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression. J Biol Chem 2000;275:6770-6.
14. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003;1619:263-8.
15. Chesire DR, Dunn TA, Ewing CM, Luo J, Isaacs WB. Identification of aryl hydrocarbon receptor as a putative Wnt/β-catenin pathway target gene in prostate cancer cells. Cancer Res 2004;64:2523-33.
16. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000;25:269-77.
17. Singal R, Ginder GD. DNA methylation. Blood 1999;93:4059-70.
18. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem 2002;277:41571-9.
19. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13.
20. Sharrard RM, Royds JA, Rogers S, Shorthouse AJ. Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer 1992;65:667-72.
21. Schulz WA, Elo JP, Florl AR, et al. Genomewide DNA hypomethylation Is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 2002;35:58-65.
22. The Japanese Urological Association and Japanese Society of Pathology, General rules for clinical and pathological studies on prostate cancer. 2nd ed. Tokyo, Japan: Kanahara-shuppan Co.; 1992.
23. Shigeno K, Igawa M, Shiina H, Kishi H, Urakami S. Transrectal colour Doppler ultrasonography for quantifying angiogenesis in prostate cancer. BJU Int 2003;91:223-6.
24. Narayan P, Dahiya R. Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J Urol 1992;148:1600-4.
25. Dahiya R, Lee C, McCarville J, Hu W, Kaur G, Deng G. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int J Cancer 1997;72:762-7.
26. Li LC, Dahiya R. Meth Primer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
27. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
28. Enokida H, Shiina H, Igawa M, et al. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 2004;64:5956-62.
29. Gibson P, Gill JH, Khan PA, et al. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther 2003;2:527-34.
30. Hudson CE, Schulte BA, Sutter TR, Morris JS. Steroid hormones modulate expression of cytochrome P450 enzymes in male hamster reproductive tract and leiomyosarcomas. Carcinogenesis 2001;22:763-70.
31. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 1992;256:1193-5.
32. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22:4632-42.
33. Takahashi Y, Suzuki C, Kamataki T. Silencing of CYP1A1 expression in rabbits by DNA methylation. Biochem Biophys Res Commun 1998;247:383-6.
34. Han X, Liehr JG. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 1994;15:997-1000.
35. Chakravarti D, Mailander PC, Li KM, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 2001;20:7945-53.
36. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235-7.
37. Tolbert PE. Oils and cancer. Cancer Causes Control 1997;8:386-405.
38. Nadon L, Siemiatycki J, Dewar R, Krewski D, Gerin M. Cancer risk due to occupational exposure to polycyclic aromatic hydrocarbons. Am J Ind Med 1995;28:303-24.